Company Contact Email:
Vision/Mission
Macrogen’s vision, "Humanizing Genomics," focuses on providing precision medicine and bioengineering services based on individual genetic traits, ultimately aiming for personalized healthcare. Our goal is to make DNA blueprints available to people around the world.
Business Description
Macrogen provides services in various fields, including personal healthcare, pet healthcare, research services (NGS, CES, microarray, etc.), and clinical services (precision medicine, genetic testing, etc.).
History
1997
Established Macrogen Inc.
2000
Established the DNA Chip Service Center
Listed on the KOSDAQ market among bio-venture firms for the first time
Analyzed Zymomonas mobilis for the first time in the world
Opened a biomedical and bioinformatics research institute
2001
Cloned mice for the first time in Korea
Completed a draft on Korean BAC Clone Map
2002
Established MGenbio Inc., a xenotransplantation-specialized company
2003
Developed BAC DNA chip
2004
Established Macrogen Young Scientist Award in the Korean Society for Biochemistry and Molecular Biology
2005
Established Macrogen, Corp. in the USA
Produced cloned pigs to cure diabetes (MGenBio)
Produced (for the first time) cloned pig for transformational anticancer substances
2006
Won approval of Array CGH DNA chips for diagnostic purpose of chromosomal abnormalities (Macrogen BAC Chips H1440) from the KFDA as IVD test
Awarded for ‘Macrogen BAC Chips H1400 (which diagnoses chromosomal abnormalities)’ at the Great Technological Contest
2007
Established Macrogen Japan Corp.
2008
Opened Macrogen European Branch (Amstelveen, Netherlands)
2010
Certified as Roche NimbleGen Array Service Provider for Korea
Joined the ‘Illumina Genome Network’ in collaboration with the Genomic Medicine Institute, Seoul National University, College of Medicine
2011
Launched the Global Premium Sequencing Brand, AxeqTM
2012
Certified CE mark of Macrogen BAC Chip H1440 for chromosomal anomalies
Established Macrogen Clinical Laboratory, Inc. in the USA
2013
MCL, Certified CLIA (Clinical Laboratory Improvement Amendments) for clinical sequencing services
2014
Contracted with Illumina as a priority client for Hiseq X Ten
MG MED, a subsidiary of Macrogen, listed on KONEX market
2015
Launched a new CI and slogan
Selected as a ‘KOSDAQ rising star 2015’ by the Korea Exchange
Selected as an institute for a ‘Young female researcher supporting program’ by the Ministry of Trade, Industry & Energy
Selected as managing institute for the ‘Development of Korean Foundation Medicine model for personalized cancer treatment’ project by the Ministry of Trade, Industry & Energy
2016
Selected as a ‘KOSDAQ rising star 2016’ by the Korea Exchange
2017
Established Macrogen Europe B.V.
Macrogen USA received CAP Accreditation
2018
Seoul HQ and Bundang PMC received CLIA Accreditation and CAP Accreditation
2019
Macrogen Research Outcome from ‘GenomeAsia 100K’ consortium Covered in Nature
2020
Macrogen picked for K-DNA Big Data Pilot Business
2021
Achieved 'ISMS-P(Personal Information & Information Security Management System)' Certification
2022
Macroge has become one of the world’s first launching partners of Illumina’s NovaSeq X series
2023
Macrogen launched personal healthcare platform ‘GenTok’
2024
Macrogen Selected as Final Contractor for Korea's Largest Bio Big Data Project
Products/Services
Macrogen provides services in various fields, including personal healthcare, pet healthcare, research services (NGS, CES, microarray, etc.), and clinical services (precision medicine, genetic testing, etc.).
Industry
Gene and genome sequencing service market
Location
https://www.macrogen.com/en/company/global-network
